CSL raises $1.5B in US bond markets to refinance debt
What's the deal? CSLDealroom has a profile for this one. Try Dealroom → has priced $1.5 billion of corporate bonds in the United States, tapping offshore debt markets to refinance its existing borrowings.
Why now? The biotech turned to US investors to roll over its debt, swapping older obligations for fresh bonds.
By the numbers: At $1.5 billion, this post-IPO debt raise ranks in the 93rd percentile among all post-IPO debt rounds for US health companies tracked in our database, drawn from a sample of 1,148.
The signal: Large, established health companies are increasingly reaching into deep US bond markets to manage their balance sheets — a sign that debt, not equity, is doing the heavy lifting for mature biotechs.
Read more: pharmadispatch.com
Image credit: Generated with Gemini
